Gritstone bio (GRTS): Price-to-Projected Revenue Ratio

GRTS (Gritstone Bio) - company brandmark

Gritstone bio, Inc. (GRTS) leads the development of personalized cancer vaccines utilizing AI. The company's P/S expectations visualize this status, although geopolitics are hindering component deliveries and patent protection. The absence of an open sales market leaves the company dependent on FDA verdicts. Meanwhile, 7.20 serves as the final level marker, helping to assess fair value in the event of a potential asset acquisition.

GRTS Gritstone Bio: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/02/2024

Analytical breakdowns for Gritstone bio (GRTS)

- stock exchange capitalization data:
Summary company analysis:Gritstone Bio GRTS
Manufactured products of gritstonebio.com

Forward P/S measures the ratio of current market capitalization to expected revenue, reflecting the market's confidence in sales growth forecasts amid volatility. The current value of 7.20 within the forward P/S of Gritstone bio, Inc. (GRTS) serves as a portfolio stress-testing tool, confirming the investment attractiveness of Gritstone bio, Inc. (GRTS) through the synergy of the EDGE AI platform and strategic alliances in the RNA vaccine sector.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple MiNK Therapeutics Inc.|Price-to-Projected Revenue Ratio werewolftx.com (HOWL)|IMMX: Future Price to Revenue|alxoncology.com - Forward Price-to-Revenue Multiple|CUE - Forward Price-to-Revenue Multiple|PDSB - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Sonnet BioTherapeutics Holdings SONN|MAIA: Forward P/S Multiple|LIMN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple LVTX|Market Cap to Projected Revenue NXTC (NextCure)|Price-to-Projected Revenue Ratio leaptx.com (LPTX)|INTS - Market Cap to Future Revenue Ratio|Forward P/S Multiple SNSE (Sensei Biotherapeutics, Inc.)|Market Cap to Expected Sales Ratio Theriva Biologics, Inc. (TOVX)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP